ACUR Acura Pharmaceuticals

Filed: 14 Jun 21, 4:20pm










Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934


Date of Report (Date of earliest event reported): June 9, 2021




(Exact Name of Registrant as specified in its Charter)



New York 1-10113 11-0853640
(State or other jurisdiction of                (Commission File Number) (I.R.S. Employer
incorporation or organization)   Identification Number)


616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip code)


(847) 705-7709

(Registrant’s telephone number, including area code)


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share ACUR 

OTCQB Market


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging Growth Company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 1.02 – Termination of a Material Definitive Agreement


On June 28, 2019, we entered into a Promissory Note with Abuse Deterrent Pharma, LLC for $6.0 million. Terms of the consolidated loan provide for a July 1, 2023 maturity date, interest at fixed rate of 7.5% per annum, and deferral of all payments of principal and interest to maturity. We also granted to Abuse Deterrent Pharma, LLC conversion rights of the $6.0 million loan into Acura common stock at $0.16 per share, issued a Warrant to purchase 10.0 million shares of the Company’s common stock at a price of $0.01 per share and granted a security interest in all Acura assets.


On June 9, 2021, we received notice of conversion from Abuse Deterrent Pharma, LLC for the $6.0 million Promissory Note and approximately $878 thousand of accrued but unpaid interest. The principal and interest were converted into 42,984,375 shares of the Company’s common stock and brings the Company’s total common shares outstanding to 65,089,043. Effective with this conversion, the Promissory Note is retired and the Company is working with Abuse Deterrent Pharma, LLC to release their security interest in all the Company’s assets.


Abuse Deterrent Pharma, LLC is our largest shareholder and, as of June 9, 2021, to our knowledge owns approximately 66% of our common stock, which does not include their Warrant to purchase 10.0 million shares of the Company’s common stock.


Mr. Schutte, as of June 9, 2021, to our knowledge owns approximately 14% of our common stock, which does not include his Warrant to purchase 1.78 million shares of the Company’s common stock. Mr. Schutte also controls MainPointe Pharmaceuticals, LLC and we have been informed by Mr. Schutte, that he is a member of Abuse Deterrent Pharma, LLC.


Item 3.02 – Unregistered Sales of Equity


The contents of Item 1.02 are incorporated herein by reference.


Item 8.01 – Other Events


On June 14, 2021, Acura Pharmaceuticals, Inc. issued a press release announcing Abuse Deterrent Pharma, LLC has elected to convert the $6.9 million outstanding principal and accrued interest. A copy of that press release is attached as Exhibit 99.1 to this report. The contents of Item 1.02 are incorporated herein by reference.


Forward-Looking Statements


Statements in the attached exhibit that are not strictly historical may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to:


·our ability to obtain funding for our continuing operations, including the development of our products utilizing our LIMITx™ and Impede® technologies;
·whether we can renegotiate the date by which we are required to obtain FDA acceptance, currently July 31, 2021, for an NDA for LTX-03 by our Agreement with Abuse Deterrent Pharma, LLC on which we depend to finance operations;
·whether our licensing partners will develop any additional products and utilize Acura for such development;
·the expected results of clinical studies relating to LTX-03, a LIMITx hydrocodone bitartrate and acetaminophen combination product, or any successor product candidate, the date by which such studies will be complete and the results will be available and whether LTX-03 will ultimately receive FDA approval;
·our business could be adversely affected by health epidemics in regions where third parties for which we rely, as in CROs or CMOs, have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely;
·whether LIMITx will retard the release of opioid active ingredients as dose levels increase;
·whether the extent to which products formulated with the LIMITx Technology reduce respiratory depression will be determined sufficient by the FDA to support approval or labelling describing safety features;
·whether LTX-03 will successfully demonstrate suitable shelf life studies;
·our and our licensee’s ability to successfully launch and commercialize our products and technologies, including Oxaydo® Tablets and our Nexafed® products;




·the results and timing of our development of our LIMITx Technology, including, but not limited to, the submission of a New Drug Application and/or FDA filing acceptance;
·our or our licensees’ ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;
·the market acceptance of, timing of commercial launch and competitive environment for any of our products;
·expectations regarding potential market share for our products;
·our ability to develop and enter into additional license agreements for our product candidates using our technologies;
·our exposure to product liability and other lawsuits in connection with the commercialization of our products;
·the increasing cost of insurance and the availability of product liability insurance coverage;
·the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;
·the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;
·whether the FDA will agree with or accept the results of our studies for our product candidates;
·the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet over-the-counter (“OTC”) Monograph standards, as applicable;
·the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;
·changes in regulatory requirements;
·adverse safety findings relating to our commercialized products or product candidates in development;
·whether the FDA will agree with our analysis of our clinical and laboratory studies;
·whether further studies of our product candidates will be required to support FDA approval;
·whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our technologies; and
·whether our product candidates will ultimately perform as intended in commercial settings.


In some cases, you can identify forward- looking statements by terms such as "may," “will”, "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," “indicates”, "projects," “predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.


Item 9.01 - Financial Statements and Exhibits


Exhibit NumberDescription
99.1Press Release of the Registrant dated June 14, 2021






Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: June 14, 2021                              ACURA PHARMACEUTICALS, INC.
 By:/s/ Peter A. Clemens
  Peter A. Clemens
                                                    Senior Vice President & Chief Financial Officer